Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about BioNTech SE
BioNTech SE News
BioNTech SE Quantitative Score
About BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
BioNTech SE Earnings & Revenue
BioNTech SE Financials
Table Compare
Compare BNTX metrics with: | |||
|---|---|---|---|
Earnings & Growth | BNTX | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | BNTX | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | BNTX | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | BNTX | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
BioNTech SE Income
BioNTech SE Balance Sheet
BioNTech SE Cash Flow
BioNTech SE Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Neutral |
| Return on Assets | Buy |
| Debt/Equity Ratio | Neutral |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Neutral |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
BioNTech SE Dividends
| Yield (TTM) | Dividend (TTM) | |
|---|---|---|
Infinity% | 2.1110 |
| Payment Date | Dividend | Frequency |
|---|---|---|
| 2022-06-17 | 2.111 | Quarterly |
BioNTech SE Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
BioNTech SE Executives
| Name | Role |
|---|---|
| Mr. Jens H. Holstein | Chief Financial Officer & Member of Management Board |
| Dr. Ugur Sahin M.D. | Co-Founder, Chief Executive Officer & Chair of the Management Board |
| Mr. Ryan Richardson | Chief Strategy Officer, MD & Member of Management Board |
| Dr. Sierk Poetting Ph.D. | MD, Chief Operating Officer & Member of Management Board |
| Dr. Ozlem Tureci M.D. | Co-Founder, Chief Medical Officer & Member of Management Board |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Jens H. Holstein | Chief Financial Officer & Member of Management Board | Male | 1963 | 1.49M |
| Dr. Ugur Sahin M.D. | Co-Founder, Chief Executive Officer & Chair of the Management Board | 1965 | 1.29M | |
| Mr. Ryan Richardson | Chief Strategy Officer, MD & Member of Management Board | Male | 1979 | 1.07M |
| Dr. Sierk Poetting Ph.D. | MD, Chief Operating Officer & Member of Management Board | 1973 | 871.81K | |
| Dr. Ozlem Tureci M.D. | Co-Founder, Chief Medical Officer & Member of Management Board | 1967 | 848.34K |